Matthew A. Coelho

The paper uses CRISPR base editing and structural analysis to identify functional residues in the PI3K pathway, revealing potential drug targets and allosteric pockets.

CRISPR-VUS identifies rare variants linked to gene dependency in cancer cell lines, prioritizing potential drivers and therapeutic targets through functional validation.

BEstimate designs and interprets CRISPR base editing experiments by predicting gRNA targets, off-targets, and providing functional annotations.

The paper identifies CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance through CRISPR screens and shows their potential as biomarkers for immunotherapy response.

This study identifies on-target WRN mutations as resistance mechanisms in MSI cancer cells to WRN helicase inhibitors and suggests combination therapies to prevent resistance.

This study links single-cell transcriptomes to genotypes to assess the functional impact of single nucleotide variants, classifying missense variants into three categories.